CO [China Cord Blood] SC 13D/A: (Original Filing)

[29 October 2015 Golden Meditech Holdings Limited 48 th 1 Garden Road Central Hong Kong Dear Sirs, Purchase Agreement dated 8 May 2015 relating to the Sale Shares and Note (“the Purchase Agreement”) We refer to the Purchase Agreement. Defined terms used in the Purchase Agreement are also used in this Letter Agreement. In accordance with Clause 3.1 of the] []

By | 2016-03-27T08:11:07+00:00 November 13th, 2015|Categories: Chinese Stocks, CO, SEC Original|Tags: , , , , , |0 Comments

CO [China Cord Blood] SC 13D/A: 29 October 2015 Golden Meditech Holdings Limited 48

[29 October 2015 Golden Meditech Holdings Limited 48 th 1 Garden Road Central Hong Kong Dear Sirs, Purchase Agreement dated 8 May 2015 relating to the Sale Shares and Note (“the Purchase Agreement”) We refer to the Purchase Agreement. Defined terms used in the Purchase Agreement are also used in this Letter Agreement. In accordance with Clause 3.1 of the] []

By | 2016-03-27T08:11:59+00:00 November 13th, 2015|Categories: Chinese Stocks, CO, Webplus ver|Tags: , , , , , |0 Comments

EVK [Ever-Glory International] 10-Q: (Original Filing)

[] [I, Edward Yihua Kang, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ending September 30, 2015 of Ever-Glory International Group, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [I, Jiansong Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ending September 30, 2015 of Ever-Glory International Group, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [Section 906 of Sarbanes-Oxley Act of 2002 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Edward Yihua Kang EX-32.1 4 f10q0915ex32i_everglory.htm CERTIFICATION] [Section 906 of Sarbanes-Oxley Act of 2002 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Jiansong Wang (Principal Financial Officer) EX-32.2 5 f10q0915ex32ii_everglory.htm CERTIFICATION]

EVK [Ever-Glory International] 10-Q:

[] [I, Edward Yihua Kang, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ending September 30, 2015 of Ever-Glory International Group, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [I, Jiansong Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ending September 30, 2015 of Ever-Glory International Group, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [Section 906 of Sarbanes-Oxley Act of 2002 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Edward Yihua Kang EX-32.1 4 f10q0915ex32i_everglory.htm CERTIFICATION] [Section 906 of Sarbanes-Oxley Act of 2002 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Jiansong Wang (Principal Financial Officer) EX-32.2 5 f10q0915ex32ii_everglory.htm CERTIFICATION]

MR [Mindray Medical International] 6-K: (Original Filing)

[Mindray Announces Third Quarter 2015 Financial Results Shenzhen, China – November 13, 2015 – Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the third quarter ended September 30, 2015. Highlights for Third Quarter 2015 - Net revenues reached $327.6 million, up 0.9% from $324.6] []

By | 2016-03-28T23:28:54+00:00 November 13th, 2015|Categories: Chinese Stocks, MR, SEC Original|Tags: , , , , , |0 Comments

SCOK [Hongli Clean Energy Technologies] 10-Q: (Original Filing)

[] [I, Jianhua Lv, certify that: (1) I have reviewed this Form 10-Q of Hongli Clean Energy Technologies Corp.; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not] [Certification of Principal Financial Officer I, Song Lv, certify that: (1) I have reviewed this Form 10-Q of Hongli Clean Energy Technologies Corp.; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the this period report fairly presents, in all material respects, the financial condition and results of operations of Hongli Clean Energy Technologies Corp. Jianhua Lv] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the this period report fairly presents, in all material respects, the financial condition and results of operations of Hongli Clean Energy Technologies Corp. Song Lv Chief Financial Officer (Principal Financial Officer)] [Hongli Clean Energy Technologies Corp. Reports Fiscal Year 2016 Q1 Financial Results 55% of Quarter’s Revenue Derived From Syngas Sales PINGDINGSHAN, China, November 13, 2015 /GlobeNewswire/ -- Hongli Clean Energy Technologies Corp. (NASDAQ: CETC) (“Hongli” or the “Company”), a vertically integrated producer of clean energy products located in Henan Province, today reported its financial results for the first quarter of]

Skip to toolbar